AstraZeneca and HUTCHMED Submit US NDA for ORPATHYS Plus TAGRISSO in Lung Cancer
Resolved · regulation · Occurred · Assessed · 1 sources
This assessment is dated 2026-09-29. Check what remains unresolved below before relying on it.
Which companies' revenue or costs change?
FDA NDA acceptance initiates the formal regulatory review timeline for savolitinib, creating milestone royalty expansion for HCM and line extension defense for AZN.
| Question | What the evidence establishes |
|---|---|
| What was reported? | Reported factAstraZeneca submitted a New Drug Application (NDA) to the US FDA for ORPATHYS (savolitinib) combined with TAGRISSO (osimertinib). |
| What else was confirmed? | Reported factThe submission targets patients with MET-driven, EGFR-mutated non-small cell lung cancer who progressed on prior EGFR-TKI therapy. |
| Does the valuation support acting? | UnknownNo stored valuation assumptions for HCM yet — this is the next research task. |
| What would change the assessment? | UnknownFDA Filing Acceptance and PDUFA Date Assignment — Monitor 60-day day filing validation notice from the US FDA |
What would this event cost your holdings?
Apply your own hypothetical returns to current holding values. The calculator does not infer security effects from this event.
Test this event against my holdingsPublic research record
Research framework · page evidenceCompleted event assessment
regulatory milestone achievement and future US commercial royalties
| Type | Claim | Scope |
|---|---|---|
| Assumption | AstraZeneca submitted a New Drug Application (NDA) to the US FDA for ORPATHYS (savolitinib) combined with TAGRISSO (osimertinib). | 2026-09-29 |
| Interpretation | regulatory milestone achievement and future US commercial royalties | HCM |
Countercase, invalidators, and sources
FDA grants Priority Review status, accelerating US commercial launch timeline into early 2027.
- · FDA Filing Acceptance and PDUFA Date Assignment — Monitor 60-day day filing validation notice from the US FDA
- HUTCHMED Announces Submission of US NDA for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung Cancer · 2026-09-29
What remains unresolved
- Base path
- Standard review proceeds with PDUFA action date scheduled within regular 10-month regulatory window.
- Adverse path
- FDA requests additional clinical subgroup data, delaying formal approval.
- Supportive path
- FDA grants Priority Review status, accelerating US commercial launch timeline into early 2027.
- · FDA Filing Acceptance and PDUFA Date Assignment — Monitor 60-day day filing validation notice from the US FDAnext month
Evidence
- HUTCHMED Announces Submission of US NDA for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung Cancer2026-09-29
“HUTCHMED announced that AstraZeneca has submitted a New Drug Application (NDA) to the FDA for ORPATHYS® (savolitinib) combined with TAGRISSO® (osimertinib) to treat patients with MET-driven EGFR-mutated non-small cell lung cancer who progressed on EGFR-TKI therapy.”
Supports: AstraZeneca submitted US NDA to FDA for ORPATHYS plus TAGRISSO combination in lung cancer.